Assessment of the effects of telmisalthan and olmethaltan on inflammation and oxidative stress in patients on maintenance hemodialysis

Assessment of the effects of telmisalthan and olmethaltan on inflammation and oxidative stress in patients on maintenance hemodialysis - Impact of telmisalthan and olmethaltan on inflammation and oxidative stress

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002413

Enrollment

Registered

2009-09-15

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease stage5d

Interventions

olmesartan termisartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Renal dysfunction: end-stage chronic kidney disease, require maintenance dialysis due to renal dysfunction 2) Expected survival time is more than 6 months 3) Aged 20 years over 4) Fully informed consent was obtained

Exclusion criteria

Exclusion criteria: 1) Patients who has past history of adverse effect of taking another ARB 2) Pregnancy 3) Patients who has serious liver disease and coronary heart disease or nephrotic syndrome 4) Hemodialysis treatment for less than six months 5) Judged inappropriate for this study by the physicians

Design outcomes

Primary

Measure	Time frame
The primary outcome is the impact of termisartan and olmesartan on blood pressure at 4, 12 and 24 months after administration of the ARB case compared with at baseline.	—

Secondary

Measure	Time frame
the secondary outcome is the impact of termisartan and olmesartan on inflammatory and oxidative stress markers (hsCRP, IL-6, IL-10. TNF, pentosidine, CML, PTX3, MPO, radical)at four and twelve months after administration of the ARB case compared with at baseline	—

Countries

Japan

Contacts

Public ContactHIROKAZU HONDA

Showa University School of Medicine Division of Nephrology Department of Medicine

hondah@med.showa-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026